Sonic Healthcare Ltd (ASX: SHL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Sonic Healthcare Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $13.48 billion
P/E Ratio 26.30
Dividend Yield 3.76%
Shares Outstanding 480.40 million
Earnings per share 1.072
Dividend per share 1.06
Year To Date Return 4.37%
Earnings Yield 3.80%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Sonic Healthcare Ltd (ASX: SHL)
    Latest News

    A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Defensive Shares

    Why the Sonic (ASX:SHL) share price could be a hidden opportunity

    The Sonic Healthcare Ltd (ASX:SHL) share price could be a hidden opportunity for investors with its high level of COVID-19…

    Read more »

    A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
    ⏸️ ASX Shares

    2 top quality blue chip ASX shares to buy in April

    Goodman Group (ASX:GMG) and this ASX blue chip share could be top options for investors in April. Here's why...

    Read more »

    fingers walking up piles of coins towards bag of cash signifying asx dividend shares
    Dividend Investing

    2 quick-growing ASX dividend shares to buy

    Kogan.com Ltd (ASX:KGN) and this ASX dividend share are growing fast. Here's why they could be great options for income investors...

    Read more »

    covid asx share price represented by man in face mask giving thumbs up
    Growth Shares

    2 COVID-19 ASX shares to buy

    There are some ASX shares that are seeing strong growth during this COVID-19 period, including Sonic Healthcare Ltd (ASX:SHL).

    Read more »

    IAG share price broker upgrade buy
    Broker Notes

    Top brokers name 3 ASX shares to buy today

    Top brokers have named Sonic Healthcare Limited (ASX:SHL) and these ASX shares as buys. Here's why they are bullish on…

    Read more »

    A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
    Share Market News

    4 ASX shares with director buys this month

    Director buys can be a sign that those most in the know view the shares as undervalued. Here are 4…

    Read more »

    Biden stimulus effect on bluescope share price represented by us dollars being printed
    Share Market News

    BlueScope (ASX: BSL) share price could get cut of Biden's US$3tn boost

    The BlueScope Steel Limited (ASX: BSL) share price could get a boost later this week thanks to US President Joe…

    Read more »

    ASX 300 share investors in suits running a race on an athletics track
    Share Market News

    Brokers think these ASX 200 shares will outperform the market

    Emerging COVID-19 trends and other news has made brokers bullish on these ASX 200 shares including Amcor (ASX: AMC) and…

    Read more »

    fingers walking up piles of coins towards bag of cash signifying asx dividend shares
    Dividend Investing

    2 growing ASX dividend shares to buy

    Sonic Healthcare Limited (ASX:SHL) and this ASX dividend shares are growing their payouts. Here's why they could be in the buy…

    Read more »

    A share market investment manager monitors share price movements on his mobile phone and laptop
    Ask a Fund Manager

    Here's an ASX tech share flying under the radar: fundie

    Ask A Fund Manager: Spaceship's Jason Sedawie reveals his most proud share purchase and the one he missed that he's…

    Read more »

    Investor sitting in front of multiple screens watching share prices
    Share Market News

    5 things to watch on the ASX 200 on Wednesday

    Qantas Airways Limited (ASX:QAN) and Santos Ltd (ASX:STO) shares will be on watch on the ASX 200 on Wednesday...

    Read more »

    Share Market News

    ASX 200 up 0.4%: Bank shares lower, Xero shares upgraded

    Australia and New Zealand Banking GrpLtd (ASX:ANZ) and Xero Limited (ASX:XRO) shares are on the move on the ASX 200…

    Read more »

    Frequently Asked Questions

    Sonic Healthcare historically makes two partially or fully franked dividend payments to shareholders each year.

    Sonic Healthcare generally pays its shareholder dividends in March and September.

    Yes, Sonic Healthcare offers a dividend reinvestment plan (DRP) as an alternative to receiving cash dividends on its ordinary shares.

    Sonic Healthcare Ltd listed on the ASX on 30 April 1987.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    04 Sep 2024 $0.6300 0.00% Final 19 Sep 2024
    01 Mar 2024 $0.4300 0.00% Interim 21 Mar 2024
    06 Sep 2023 $0.6200 100.00% Final 21 Sep 2023
    07 Mar 2023 $0.4200 100.00% Interim 22 Mar 2023
    06 Sep 2022 $0.6000 100.00% Final 21 Sep 2022
    08 Mar 2022 $0.4000 100.00% Interim 23 Mar 2022
    07 Sep 2021 $0.5500 65.00% Final 22 Sep 2021
    09 Mar 2021 $0.3600 30.00% Interim 24 Mar 2021
    07 Sep 2020 $0.5100 30.00% Final 22 Sep 2020
    10 Mar 2020 $0.3400 30.00% Interim 25 Mar 2020
    10 Sep 2019 $0.5100 30.00% Final 25 Sep 2019
    08 Mar 2019 $0.3300 20.00% Interim 26 Mar 2019
    12 Sep 2018 $0.4900 30.00% Final 27 Sep 2018
    06 Mar 2018 $0.3200 20.00% Interim 10 Apr 2018
    08 Sep 2017 $0.0000 0.00% Final 11 Oct 2017
    07 Mar 2017 $0.3100 20.00% Interim 11 Apr 2017
    08 Sep 2016 $0.4400 30.00% Final 27 Sep 2016
    03 Mar 2016 $0.3000 30.00% Interim 06 Apr 2016
    05 Sep 2014 $0.4000 55.00% Final 23 Sep 2014
    03 Sep 2012 $0.2923 53.88% Final 09 Oct 2012
    04 Mar 2011 $0.1881 35.62% Interim 24 Mar 2011
    08 Sep 2010 $0.2818 43.47% Final 28 Sep 2010
    03 Mar 2010 $0.1932 43.48% Interim 25 Mar 2010
    08 Sep 2009 $0.2818 43.47% Final 28 Sep 2009
    05 Mar 2009 $0.1936 68.18% Interim 26 Mar 2009
    08 Sep 2008 $0.3200 100.00% Final 09 Oct 2008
    28 Feb 2006 $0.1500 100.00% Interim 20 Mar 2006
    31 Aug 2005 $0.2300 100.00% Final 19 Sep 2005
    26 Feb 2004 $0.1000 100.00% Interim 17 Mar 2004

    SHL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Sonic Healthcare Ltd

    Sonic Healthcare Limited (ASX: SHL) is a global healthcare provider. It is the largest private medical laboratory and pathology services operator in Australia, the United Kingdom, Germany, and Switzerland. It is the second-largest provider in Belgium and New Zealand and the third-largest in the United States.

    While pathology contributes the vast majority of the company's revenue, Sonic Healthcare is also a major provider of diagnostic imaging in Australia and is the largest medical centre operator in the country.

    The company typically earns the majority of its revenue from its European pathology segment, followed by its Australia-New Zealand pathology operations.  

    SHL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    08 Jan 2025 $28.24 $0.05 0.18% 672,266 $28.11 $28.37 $28.00
    07 Jan 2025 $28.19 $0.36 1.29% 802,609 $27.90 $28.34 $27.84
    06 Jan 2025 $27.83 $0.27 0.98% 573,883 $27.77 $27.92 $27.70
    03 Jan 2025 $27.56 $0.21 0.77% 534,513 $27.35 $27.60 $27.29
    02 Jan 2025 $27.35 $0.34 1.26% 498,233 $26.99 $27.39 $26.91
    31 Dec 2024 $27.01 $-0.22 -0.81% 592,751 $27.02 $27.23 $26.90
    30 Dec 2024 $27.23 $-0.21 -0.77% 680,326 $27.26 $27.33 $27.03
    27 Dec 2024 $27.44 $-0.12 -0.44% 640,370 $27.48 $27.53 $27.26
    24 Dec 2024 $27.56 $0.15 0.55% 312,689 $27.42 $27.68 $27.36
    23 Dec 2024 $27.41 $0.24 0.88% 561,166 $27.48 $27.55 $27.25
    20 Dec 2024 $27.17 $-0.33 -1.20% 2,122,041 $27.44 $27.60 $27.04
    19 Dec 2024 $27.50 $-0.42 -1.50% 1,260,886 $27.48 $27.65 $27.30
    18 Dec 2024 $27.92 $-0.14 -0.50% 1,089,050 $28.15 $28.19 $27.79
    17 Dec 2024 $28.06 $0.27 0.97% 1,000,471 $27.65 $28.25 $27.61
    16 Dec 2024 $27.79 $-0.23 -0.82% 1,056,208 $27.97 $28.00 $27.70
    13 Dec 2024 $28.02 $-0.08 -0.28% 743,483 $27.97 $28.20 $27.92
    12 Dec 2024 $28.10 $-0.18 -0.64% 702,765 $28.19 $28.40 $28.06
    11 Dec 2024 $28.28 $-0.16 -0.56% 997,730 $28.48 $28.63 $28.28
    10 Dec 2024 $28.44 $-0.16 -0.56% 1,324,160 $28.84 $28.84 $28.44

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    11 Dec 2024 Christine Bennett Buy 1,000 $28,483
    On-market trade.
    10 Dec 2024 Kathryn (Kate) Spargo Buy 1,500 $42,765
    On-market trade.
    10 Dec 2024 Mark Compton Buy 1,000 $28,460
    On-market trade.
    09 Dec 2024 Suzanne Crowe Buy 348 $9,991
    On-market trade.
    19 Nov 2024 Christopher Wilks Issued 27,570 $771,684
    Issue of securities. 75,994 Rights
    19 Nov 2024 Christopher Wilks Issued 142,746 $3,995,460
    Issue of options.
    19 Nov 2024 Christopher Wilks Expiry 181,147 $5,070,304
    Options expired.
    19 Nov 2024 Colin Goldschmidt Issued 65,700 $1,838,943
    Issue of securities. 182,000 Rights
    19 Nov 2024 Colin Goldschmidt Issued 340,163 $9,521,162
    Issue of options.
    19 Nov 2024 Colin Goldschmidt Expiry 407,747 $11,412,838
    Options expired.
    27 Sep 2024 Christopher Wilks Expiry 11,264 $300,636
    As advised by the company. Forfeited
    27 Sep 2024 Christopher Wilks Expiry 71,059 $1,896,564
    Options expired.
    27 Sep 2024 Colin Goldschmidt Expiry 29,557 $788,876
    As advised by the company. forfeited, 116,300 Rights
    27 Sep 2024 Colin Goldschmidt Expiry 186,467 $4,976,804
    Options expired.
    23 Sep 2024 Colin Goldschmidt Transfer 41,663 $1,089,070
    As advised by the company. legally transferred into Dr Goldschmidt's name.
    23 Sep 2024 Colin Goldschmidt Transfer 41,663 $1,089,070
    As advised by the company. legally transferred into Dr Goldschmidt's name.
    23 Sep 2024 Christopher Wilks Transfer 21,711 $567,525
    As advised by the company. legally transferred into Mr Wilks name.
    23 Sep 2024 Christopher Wilks Transfer 21,711 $567,525
    As advised by the company. legally transferred into Mr Wilks name.
    29 May 2024 Christine Bennett Buy 1,000 $24,010
    On-market trade.
    23 May 2024 Suzanne Crowe Buy 2,000 $50,639
    On-market trade.
    23 May 2024 Mark Compton Buy 1,000 $25,350
    On-market trade.
    22 May 2024 Katharine Giles Buy 500 $12,357
    On-market trade.
    19 Apr 2024 Christine Bennett Transfer 2,000 $54,580
    Off-market transfer.
    19 Apr 2024 Christine Bennett Transfer 2,000 $54,580
    Off-market transfer.
    05 Mar 2024 Christine Bennett Buy 1,100 $31,373
    On-market trade.
    01 Mar 2024 Christopher Wilks Buy 16,187 $471,851
    Conversion of securities.
    01 Mar 2024 Christopher Wilks Buy 5,863 $170,906
    Conversion of securities.
    01 Mar 2024 Christopher Wilks Exercise 22,050 $642,757
    Conversion of securities. 59,688 Rights
    01 Mar 2024 Colin Goldschmidt Exercise 52,695 $1,536,059
    Conversion of securities. 1,45,857 Rights
    01 Mar 2024 Colin Goldschmidt Buy 10,217 $297,825
    Conversion of securities.
    01 Mar 2024 Colin Goldschmidt Buy 42,478 $1,238,233
    Conversion of securities.
    22 Feb 2024 Katharine Giles Buy 250 $7,222
    On-market trade. 2,500 Prior holding

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Christopher David Wilks Chief Financial OfficerFinance Director Dec 1989
    Mr Wilks has a background in chartered accounting and investment banking and was previously a partner in a private investment bank. Mr Wilks has held directorships in a number of public companies and is currently a Non-executive Director of Silex Systems Limited (since 1988), a listed company divested by Sonic in 1996.
    Dr Colin Stephen Goldschmidt Chief Executive OfficerManaging Director Jan 1993
    Dr Goldschmidt became CEO of Sonic has led Sonic's global expansion by committing the Company to a unique model of Medical Leadership, which incorporates operational and cultural attributes focussed on care for staff and quality service to doctors and patients. He is a member of Risk Management Committee and holds memberships with industry, medical and laboratory associations.
    Mr Mark Raymond Compton Non-Executive DirectorNon-Executive Chairman Oct 2014
    Mr Compton has senior executive experience in healthcare services. He is currently Adjunct Professor in Management (Healthcare Leadership) at Macquarie University (Macquarie Business School), Non-executive Director of The Hospitals Contribution Fund of Australia and Non-executive Chairman of not for-profit organisations St Luke's Care and the Order of St John (St John Ambulance). His previous experience includes Chief Executive Officer of each of St Luke's Care, Immune Systems Therapeutics Limited and the Royal Flying Doctor Service of Australia. Prof. Compton has also held a number of non-executive director roles. He was also Chairman of the Woolcock Institute of Medical Research, Non-executive Director of Macquarie University Hospital and Chairman and Chancellor of St John Ambulance Australia (having served as a volunteer for more than 45 years).
    Mr Neville Mitchell Non-Executive Director Sep 2017
    Mr Mitchell has international healthcare and finance experience. He was Chief Financial Officer and Company Secretary of ASX-listed Cochlear Limited (until March 2017), a medical device developer, manufacturer and seller of hearing devices. He was formerly a Non-executive Director of QBiotics Group Limited (from November 2017 to May 2023). He has also performed roles with a number of industry and government committees. Mr Mitchell is member of the Risk Management Committee.
    Professor Suzanne Crowe Non-Executive Director Apr 2020
    Professor Crowe was a Non-executive Director of St Vincent's Health Australia Ltd from January 2013 until October 2021. She retired from Burnet Institute as Associate Director in 2018 following a 30-year research career, having played a role in Burnet's development as a global research organisation. Professor Crowe retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne in 2019 after 35 years of service. She has served as a Member of the Prime Minister's Science Engineering and Innovation Council (India/China Working Group), as Head of the World Health Organization (WHO) Regional Reference Laboratory for HIV Resistance Testing and as an HIV advisor to WHO for 25 years. She was appointed a Fellow of the Australian Academy of Health and Medical Sciences in 2015. Professor Crowe is Chair of the Risk Management Committee.
    Professor Christine Constance Bennett Non-Executive Director Sep 2022
    Ms Bennett has over 40 years of healthcare industry experience across the private, public and not-for-profit sectors. Professor Bennett is an experienced non-executive director in for profit and social enterprises and is currently a Non-executive Director of Convenor of the Champion of Change Health Group for gender equality. She is an advisor to the Digital Health Cooperative Research Centre and in 2024 completed a certificate on AI Ethics and Board Oversight. Her previous Board non-executive director roles include Telstra Health, HeartWare Limited, Symbion Health Limited and Chair of Sydney Children's Hospital Network. In December 2021, Professor Bennett retired from The University of Notre Dame Australia where she was Deputy Vice Chancellor, Enterprise & Partnerships and Dean, School of Medicine, Sydney for over ten years. Her prior experience has included being Group Executive and Chief Medical Officer for MBF and then Bupa Health and Care Services; CEO and later Chair of Research Australia; Managing Director of Total Health Enterprise Ltd; Partner in Health and Life Sciences for KPMG Australia; CEO of Westmead Hospital and Community Health Services; General Manager for the Royal Hospital for Women; and Head of Planning in NSW Health. Professor Bennett has a commitment to and involvement in medical professional issues, public policy and medical research. In 2008 she was appointed as Chair of the National Health and Hospitals Reform Commission producing a long-term blueprint for reform of health and aged care in Australia. Professor Bennett is a member of the Risk Management Committee.
    Ms Kathryn (Kate) Dianne Spargo Non-Executive Director Jul 2010
    Ms Spargo has gained business experience as a legal advisor, having worked in private practice and government, and as a director. Ms Spargo has been a director of both listed and unlisted companies over the last 20 years. Ms Spargo also holds non-executive director roles with CIMIC Group Limited, the Future Fuels Cooperative Research Centre and Geelong Football Club Limited. Ms Spargo was previously a Non-executive Director of Fletcher Building Limited, Xenith IP Group Limited and Adairs Limited (from May 2015 to 11 September 2024).
    Dr Katharine Giles Non-Executive Director Sep 2022
    Dr Giles, after initially practicing as a medical doctor, moved to commercial pursuits which combined science, medicine and health. Dr Giles is currently Managing Director and Chief Executive Officer of OncoRes Medical (since 2017), which is developing a novel imaging technology to improve cancer outcomes. Dr Giles is also a Venture Partner at Brandon Capital Partners (since 2012), a venture capital firm dedicated to developing and supporting Australian life sciences businesses. She was previously an Investment Manager with Stone Ridge Ventures, a fund manager specialising in seed-to-early-stage technology investment. Dr Giles has start-up experience in medical apps, diagnostics and fitness devices and has served on the boards of private health care related technology companies. She is a member of the Curtin University Commercialisation Advisory Board and currently serves on the board of the Australian Government's National Reconstruction Fund.
    Mr Paul Joseph Alexander Company SecretaryDeputy Chief Financial Officer
    -
    Paul Joseph Alexander Company SecretaryDeputy Chief Financial Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 161,840,103 33.69%
    J P Morgan Nominees Australia Pty Limited 60,610,409 12.62%
    Citicorp Nominees Pty Limited 42,296,322 8.80%
    Jardvan Pty Ltd 15,109,474 3.15%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 8,796,938 1.83%
    BNP Paribas Noms Pty Ltd 6,701,631 1.39%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 5,284,606 1.10%
    National Nominees Limited 4,967,870 1.03%
    Argo Investments Limited 3,726,053 0.78%
    Netwealth Investments Limited <Wrap Services A/C> 3,565,479 0.74%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,461,262 0.72%
    Australian Foundation Investment Company Limited 3,159,672 0.66%
    Washington H Soul Pattinson And Company Limited 2,326,857 0.48%
    IOOF Investment Services Limited <Ips Superfund A/C> 1,914,028 0.40%
    Gerhard Risch 1,864,163 0.39%
    Blaise Mentha 1,850,000 0.39%
    Polly Pty Ltd <A/C Patterson Family> 1,817,416 0.38%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 1,713,397 0.36%
    Quintal Pty Ltd <Harken Family A/C> 1,587,908 0.33%
    Netwealth Investments Limited <Super Services A/C> 1,569,741 0.33%

    Profile

    since

    Note